Related Experiment Video
Updated: Aug 26, 2025

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution
Published on: February 24, 2015
CARM1-mediated methylation of ASXL2 impairs tumor-suppressive function of MLL3/COMPASS
Zibo Zhao1, Emily Jane Rendleman1, Aileen Patricia Szczepanski1
1Simpson Querrey Center for Epigenetics, Northwestern University Feinberg School of Medicine, 303 East Superior Street, Chicago, IL 60611, USA.
Abstract:
An imbalance in the activities of the Polycomb and Trithorax complexes underlies numerous human pathologies, including cancer. The BRCA1 associated protein-1 (BAP1) deubiquitinase negatively regulates Polycomb activity and recruits the Trithorax histone H3K4 methyltransferase, mixed-lineage leukemia protein 3 (MLL3) within Complex Proteins Associated with Set1 (COMPASS), to the enhancers of tumor suppressor genes. We previously demonstrated that the BAP1-MLL3 pathway is mutated in several cancers, yet how BAP1 recruits MLL3 to its target loci remains an important unanswered question. We demonstrate that the ASXL2 subunit of the BAP1 complex mediates a direct interaction with MLL3/COMPASS. ASXL2 loss results in decreased MLL3 occupancy at enhancers and reduced BAP1-MLL3 target gene expression. Interaction between ASXL2 and MLL3 is negatively regulated by protein arginine methyltransferase 4 (PRMT4/CARM1), which methylates ASXL2 at R639/R641. ASXL2 methylation blocks binding to MLL3 and impairs the expression of MLL3/COMPASS-dependent genes. This previously unidentified transcriptional repressive function of CARM1 provides insight into the BAP1/MLL3-COMPASS axis and reveals a potential cancer therapeutic target.
Insights
ASXL2 directly binds to MLL3/COMPASS, mediating BAP1
Area of Science:
- Epigenetics
- Molecular Biology
- Cancer Biology
Background:
- Polycomb and Trithorax complexes regulate gene expression and are implicated in cancer.
- BRCA1 associated protein-1 (BAP1) deubiquitinase regulates Polycomb activity and recruits MLL3/COMPASS to tumor suppressor gene enhancers.
- The BAP1-MLL3 pathway is frequently mutated in various cancers.
Purpose of the Study:
- To elucidate the mechanism by which BAP1 recruits MLL3/COMPASS to target gene loci.
- To investigate the role of ASXL2 in mediating the BAP1-MLL3 interaction.
- To identify regulatory mechanisms controlling the BAP1-MLL3-COMPASS axis.
Main Methods:
- Co-immunoprecipitation assays to demonstrate ASXL2-MLL3 interaction.
- Chromatin immunoprecipitation sequencing (ChIP-seq) to assess MLL3 occupancy.
- Quantitative PCR (qPCR) to measure gene expression levels.
- Mass spectrometry to identify ASXL2 methylation sites.
Main Results:
- ASXL2 subunit of the BAP1 complex directly interacts with MLL3/COMPASS.
- Loss of ASXL2 leads to reduced MLL3 binding at enhancers and decreased target gene expression.
- Protein arginine methyltransferase 4 (PRMT4/CARM1) methylates ASXL2 at R639/R641, inhibiting MLL3 binding.
- CARM1-mediated methylation of ASXL2 represses MLL3/COMPASS-dependent gene expression.
Conclusions:
- ASXL2 is a crucial mediator of BAP1 recruitment of MLL3/COMPASS to target enhancers.
- PRMT4/CARM1 antagonizes the BAP1-MLL3-COMPASS transcriptional activation complex through ASXL2 methylation.
- This study reveals a novel repressive role for CARM1 and identifies a potential therapeutic target in the BAP1-MLL3-COMPASS pathway for cancer treatment.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Epigenetic Regulation
Induced Pluripotent Stem Cells
Somatic...
Inheritance of Chromatin Structures
MicroRNAs
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

